ID: ALA5173948

Max Phase: Preclinical

Molecular Formula: C32H44O7

Molecular Weight: 540.70

Associated Items:

Representations

Canonical SMILES:  CCCCCC(=O)OCC(=O)O[C@@H]1C[C@]2(C(C)C)O[C@@]1(C)[C@@H]1CC[C@@H](C)[C@H]1[C@@H]2OC(=O)/C=C/c1ccccc1

Standard InChI:  InChI=1S/C32H44O7/c1-6-7-9-14-26(33)36-20-28(35)37-25-19-32(21(2)3)30(29-22(4)15-17-24(29)31(25,5)39-32)38-27(34)18-16-23-12-10-8-11-13-23/h8,10-13,16,18,21-22,24-25,29-30H,6-7,9,14-15,17,19-20H2,1-5H3/b18-16+/t22-,24-,25-,29-,30+,31+,32-/m1/s1

Standard InChI Key:  ADDYXRJAOHCVHG-BEHXIQGFSA-N

Associated Targets(Human)

A498 42825 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

UO-31 46270 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

RXF 393 41971 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Short transient receptor potential channel 4 17 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Short transient receptor potential channel 5 300 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 540.70Molecular Weight (Monoisotopic): 540.3087AlogP: 5.90#Rotatable Bonds: 11
Polar Surface Area: 88.13Molecular Species: NEUTRALHBA: 7HBD: 0
#RO5 Violations: 2HBA (Lipinski): 7HBD (Lipinski): 0#RO5 Violations (Lipinski): 2
CX Acidic pKa: CX Basic pKa: CX LogP: 6.86CX LogD: 6.86
Aromatic Rings: 1Heavy Atoms: 39QED Weighted: 0.15Np Likeness Score: 1.85

References

1. Seenadera SPD, Long SA, Akee R, Bermudez G, Parsonage G, Strope J, Peer C, Figg WD, Parker KA, Beech DJ, Beutler JA..  (2022)  Biological Effects of Modifications of the Englerin A Glycolate.,  13  (9.0): [PMID:36105325] [10.1021/acsmedchemlett.2c00258]

Source